Peer-reviewed veterinary case report
Survival time and outcomes for dogs with Cushing's disease in England
By Schofield, Imogen et al.·Published in The Veterinary record·2020·Royal Veterinary College, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Survival analysis of 219 dogs with hyperadrenocorticism attending primary care practice in England.
- Species:
- dog
Plain-English summary
A group of 219 dogs diagnosed with hyperadrenocorticism (a hormone disorder) were studied to understand their survival rates after diagnosis. Unfortunately, 81.7% of these dogs passed away during the study, with an average survival time of about 510 days. Most dogs were treated with a medication called trilostane, and those who had their dose increased showed better outcomes. Larger dogs and older dogs had a higher risk of passing away from this condition. Overall, while many dogs lived for a significant time after diagnosis, the prognosis varied based on age and weight.
People also search for: dog hyperadrenocorticism treatment · trilostane for dogs · dog Cushing's disease survival rate
Abstract
BACKGROUND: Hyperadrenocorticism is an endocrine disease routinely encountered within primary care practice; however, few studies evaluating survival beyond diagnosis have studied this population. METHODS: This retrospective cohort study analysed the electronic patient records of 219 cases of hyperadrenocorticism from a sample of dogs attending primary care practices in England. Kaplan-Meier plots examined the cumulative survival and Cox proportional hazard regression modelling identified factors associated with the hazard of all-cause mortality. RESULTS: In the analysis, 179/219 (81.7 per cent) hyperadrenocorticism cases died during the study period with a median survival time from first diagnosis of 510 days (95% CI 412 to 618 days). Trilostane was used in 94.1 per cent of cases and differentiation between pituitary-dependent and adrenal-dependent disease was made in 20.1 per cent of cases. In the multivariable analysis, dogs weighing greater than or equal to 15 kg (HR 1.51, 95% CI 1.06 to 2.15, P=0.023) and those diagnosed greater than or equal to 13 years of age (HR 3.74, 95% CI 2.29 to 6.09, P<0.001) had increased hazards of all-cause mortality. Dogs that had their initial trilostane dose increased had a favourable prognosis (HR 0.49, 95% CI 0.32 to 0.76, P=0.015). CONCLUSION: This study shows that survival from diagnosis of hyperadrenocorticism appears fair for many dogs and provides primary care practitioners with relatable benchmark prognostic figures.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31542726/